Law360, New York (June 27, 2012, 3:26 PM ET) -- The U.S. Food and Drug Administration on Wednesday gave its blessing to Arena Pharmaceuticals Inc.’s weight-loss treatment Belviq, the first such approval in more than a decade and a potential milestone in the nation’s obesity epidemic.
The agency’s action came after years of trouble for diet drugs, which had their reputations tarnished by heart problems associated with fen-phen. The last obesity drug endorsed by the FDA was Roche Holding AG's Xenical, and since it won agency backing in 1999, American waistlines have grown consistently larger....
Arena's Belviq 1st Obesity Drug To Get FDA's Nod Since 1999
To view the full article, take a free trial now.
